HOUSE_OVERSIGHT_028415.jpg

2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press"},"identifier":"100000006098011 Sba8b80411187", "imageIdentifier":"el26e7bde26613f 50f2609cb8776d827", "layout": "fullbleed- image", "role":"photo", "type": "scalable image"}, {"identifier":" anf-caption- 1","inlineTextStyles": [{"range":{"length":27, "start ":261},"textStyle": "photo- credit"}],"layout":"default-caption", "role": "caption", "text":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press ","type"™:"text"}],"identifier":" anf-container- 5","layout"™:"image- container", "role":"container", "type": "container"}],"identifier":" anf-section- 2","layout":"default- section", "role":"section", "scene": {"fadeColor":"#FFFFFF","type":"fading sticky header"} ,"type™:"section"}, {"additions": [{"URL":"https://www.businesswire.com/news/home/2018012 9005762/en/Celgene-Announces-Retirement-Executive-Chairman-Bob- Hugin", "range": {"length":34,"start":194},"type":"link"}],"identifier":" anf-body- 6", "inlineTextStyles": [{"range": {"length":363,"start":0},"textstyle":" anf-ts- I"}, {"range™: {"length":363,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"When Bob Hugin joined Celgene in 1999 as its chief financial officer, the company was a struggling biotech that sold just one product ae" a leprosy drug 4€" and faced a shaky future. By the time he stepped down as executive chairman in February to run for United States Senate, Celgene had become a pharmaceutical powerhouse with a market value of nearly $80 billion.","type":"text"}, {"additions": [{"URL":"https://ir.celgene.com/press- releases/press-release-details/2018/Celgene-Reports-Fourth-Quarter-and-Full-Year-2017 Operating-and-Financial- Results/default.aspx", "range": {"length":17, "start ":177},"type™:"Link"}],"identifier™:" | anf-body-7", "inlineTextStyles": [{"range"™:{"length":195,"start":0},"textStyle":" anf-ts- I"}, {"range"™:{"length":195,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"And that onetime leprosy drug? It had been transformed into Revlimid, a best-selling cancer drug that, with annual sales of $8.2 billion, made up nearly two-thirds of Celgened€™s net sales in 2017.","type™:"text"}, {"additions"™: [{"URL":"https://youtu.be/K4Agl kLfs5w", "range": {"len gth":34,"start":174},"type"™:"link"}],"identifier":" anf-body- 8", "inlineTextstyles": [{"range"<:{"length":324,"start":0},"textstyle":" anf-ts-— I"}, {"range™: {"length":324,"start":0},"textStyle":" anf-ts-1"}],"layout":"default— body", "role": "body", "text":"Mr. Hugin, a Republican mounting a surprisingly strong challenge to Senator Robert Menendez in New Jersey, has made his career at Celgene a cornerstone of his campaign, with television advertisements boasting that he d4€cechose a life of serviced€ in the Marines and a€eleading a health care company that develops cancer medicine.a€", "type": "text"}, {"identifier":" anf-body- 9","inlineTextStyles": [{"range":{"length":299, "start":0},"textstyle":" anf-ts- i"},{"range"™:{"length":299,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"In deeply blue New Jersey, few expected a real contest for Mr. Menendezad€™s seat. Yet anger stemming from Mr. Menendezad€™s federal corruption trial last year 4€" a trial that Mr. Huginad€™s campaign reminds television viewers in New Jersey about on a regular basis a€" has dampened his popularity among voters.","type":"text"}, {"bannerType"™: "any", "identifier":" anf-banner advertisement i", "layout": "ComponentLayout-— 4","role":"banner advertisement", "type":"banner advertisement"}, {"additions":[{"URL™:"h ttps://twitter.com/realDonaldTrump/status/1016368503723577344", "range": {"length":21,"st art ™:213}, "type™:"link"}, {"URL":"https://news.gallup.com/poll1/12748/business-industry- sector- ratings.aspx", "range": {"length":16, "start ":238},"type"™:"link"}],"identifier":" anf- body-10", "inlineTextStyles": [{"range"™:{"length":413,"start":0},"textStyle":" anf-ts- I"}, {"range"™: {"length":413,"start":0},"textStyle":" anf-ts-1"}],"layout":"default— body", "role":"body", "text": "But Mr. Hugind€™s professional career could also prove to be a liability d4€" he is the sole pharmaceutical executive running for statewide office in 2018. Anger over high drug prices has risen and President Trump has vilified the industry. A 2017 Gallup poll found that just 33 percent of the country had a favorable view of the drug industry, the second-lowest of any sector. (The lowest was the federal government.)","type":"text"}, {"identifier":" anf-body- 11i","inlineTextStyles":[{"range":{"length":394,"start":0},"textStyle":" anf-ts- HOUSE_OVERSIGHT_028415